DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves premarket: Macy's, Tesla, Novo Nordisk and more
▼ + stars: | 2024-07-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Crypto stocks — Stocks tied to bitcoin price slid after the cryptocurrency dropped 5% to its lowest level since February , with the now defunct Mt. Macy's — Shares of the retailer jumped more than 6% following a Wall Street Journal report that an investor group has hiked its takeout offer. Arkhouse Management and Brigade Capital Management are now offering about $24.80 per share for Macy's, up from $24 previously, the report said. Tesla — The electric vehicle manufacturer popped 2%, marking a continuing comeback after its second-quarter vehicle deliveries number beat analyst estimates earlier this week. Shell — Shares popped 1%.

Persons: Stocks, Energy, CleanSpark, Instructure, Tesla, CNBC's Hakyung Kim, Tanaya Macheel, Sarah Min, Jesse Pound Organizations: Marathon, Francisco Partners, KKR, Reuters, Macy's, Journal, Arkhouse Management, Brigade Capital Management, Novo Nordisk —, Harvard, Novo Nordisk's Ozempic, Deutsche Bank, Shell Locations: Novo, Singapore, Rotterdam

☆ Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
▼ + stars: | 2024-07-04 | by ( April Roach | ) www.cnbc.com time to read: +2 min

Novo Nordisk investors appeared unperturbed Thursday by a critical Harvard report that linked weight loss drugs to a rare eye condition. Semaglutide, which is present in weight loss drugs including Novo Nordisk's Ozempic and Wegovy, might be associated with an increased risk of a rare eye disease, according to a study carried out by Harvard Medical School. Patients were more likely to be diagnosed with the eye condition compared to patients who were not prescribed the weight loss drugs, the study found. A spokesperson from Novo Nordisk said the optic nerve disease NAION is not an "adverse drug reaction for the marketed formulations of semaglutide" as per the approved labels. "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously," the spokesperson said.

Persons: Emmanuel Papadakis Organizations: Novo Nordisk, Harvard, Novo Nordisk's Ozempic, Harvard Medical School, Analysts, Deutsche Bank Locations: London

☆ Patients on Ozempic are developing a rare form of sudden blindness, doctors say
▼ + stars: | 2024-07-03 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +3 min

Eye doctors in Boston have started to notice a small but worrisome uptick in cases of a rare type of sudden blindness among patients taking semaglutide. (Semaglutide is the active ingredient in two Novo Nordisk drugs: Ozempic for type 2 diabetes and Wegovy for obesity.) Rare, and notableThe number of patients on semaglutide who developed NAION was tiny: Out of more than 16,000 eye patients in Massachusetts included in this six-year retrospective investigation, only 37 people on semaglutide developed NAION. Patients with diabetes and high blood pressure have always been at an increased risk of developing eyesight issues. (Novo Nordisk is working on another, separate study, testing whether semaglutide might be useful in treating diabetic retinopathy.)

Persons: semaglutide, Dr, Joseph Rizzo Organizations: Service, Business, Ophthalmology, Novo Nordisk, Harvard Medical School Locations: Boston, Massachusetts, Novo, semaglutide

☆ Popular weight loss and diabetes drugs linked to increased risk of rare form of blindness
▼ + stars: | 2024-07-03 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +6 min

CNN —People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide. Semaglutide prescriptions have soared in the US, which could raise the number of people at risk for a potential side effect. But the large number of people who are taking semaglutide should raise confidence that the absolute risk of developing NAION as a result is rare.

Persons: ”, Joseph Rizzo, ” Susan Mollan, Disha, Dr, Sanjay Gupta, Chanapa, Andrew Lee, ” Narang Organizations: CNN —, Mass, Novo Nordisk, CNN, Harvard Medical School, ”, University Hospitals Birmingham, Endeavor Health, CNN Health, US Food and Drug Administration, FDA, American Academy of Ophthalmology, Houston Methodist Hospital Locations: Chicago

☆ Novo Nordisk's Wegovy weight loss drug approved in China
▼ + stars: | 2024-06-25 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world's second largest economy. China's National Medical Products Administration "recently" approved the weekly injectable drug, Novo Nordisk said in a press release on the Chinese version of its website, according to Google translate. Novo Nordisk did not immediately respond to CNBC's request for further information on the proposed pricing and rollout timeline of the drugs. The company's Ozempic diabetes drug was approved in 2021 and saw sales in the greater China region double last year. On Monday, Novo Nordisk announced it is investing $4.1 billion to expand its manufacturing in the U.S.

Persons: —, Eli Lilly Organizations: Novo Nordisk, Medical Products Administration, Google, Reuters, National Health Commission, U.S Locations: China, Danish, London, Clayton , North Carolina

☆ Children with high BMIs should not use obesity medications like WeGovy, US doctors warn
▼ + stars: | 2024-06-19 | by ( Julia Naftulin | ) www.businessinsider.com time to read: +4 min

Read previewWith weight-loss drugs like WeGovy and Ozempic dominating many of today's consumer healthcare conversations, there's a mounting concern for a particularly vulnerable group: children. In January 2023, the American Academy of Pediatrics (AAP) recommended that healthcare providers offer weight-loss medications, in addition to lifestyle adjustments, to treat obesity in children 12 and older. And in addition, there was limited evidence on weight loss maintenance after medications were discontinued in children," Nicholson said. These injectable drugs have proven successful as weight-loss interventions for adults with obesity, early research shows. Nicholson said clinicians have used lifestyle interventions, like nutrition and exercise plans, to help children with obesity lose weight and reduce risk factors like hypertension, diabetes, and liver disease.

Persons: —, Eli Lilly, Hilary Brueck, Wanda Nicholson, Nicholson, Amanda Staiano, Staino Organizations: Service, Pharmaceutical, Novo Nordisk, Business, American Academy of Pediatrics, US Preventive Services, Force, George Washington University School of Public Health, FDA, Pennington Biomedical Research, of Louisiana State University Locations: Pennington

☆ To help children with high BMI, expert panel recommends 26 hours of behavior coaching — but not weight-loss drugs
▼ + stars: | 2024-06-18 | by ( Jen Christensen | ) edition.cnn.com time to read: +9 min

The task force suggested that extensive and intensive behavioral interventions are the best way to help a child get to a healthy weight. A high BMI for a child is defined a little differently than it is for adults, although both use height and weight to estimate mass. Nearly 20% of children in the US have what’s considered a high BMI. The task force gives its guidelines letter grades based on the most up-to-date science. Under the Affordable Care Act, private insurers must cover preventive services that get a grade of A or B; the new child obesity recommendations got a B grade.

Persons: Susma Vaidya, ”, “, Dr, Mona Sharifi, ” Sharifi, Thomas Robinson, Sarah Armstrong, haven’t, Sharifi, Justin Ryder, Stanley Manne, Robert H, Lurie, “ I’ve, ” Ryder, Wegovy, Alli, Lomaira, John Ruiz, Sanjay Gupta, “ There’s, ” Vaidya, Vaidya, pharmacotherapy Organizations: CNN, US Preventive Services, Force, American Academy of Pediatrics, BMI, US Centers for Disease Control, Affordable, National Hospital, Yale School of Medicine, Stanford Solutions Science Lab, Department of Pediatrics, Pediatrics, Adolescent Health, Duke University Medical School, Stanley Manne Children’s, Ann, Lurie Children’s Hospital of Chicago, University of Arizona, CNN Health, FDA Locations: Washington

☆ The number of Ozempic and Wegovy scams has grown by 183% so far this year
▼ + stars: | 2024-06-15 | by ( Kenneth Niemeyer | ) www.businessinsider.com time to read: +1 min

Phishing scams targeting weight loss drugs like Ozempic rose 183% from January to April. Social media sites like Facebook are hotspots for these scams, McAfee says. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . The trendy weight loss drug Ozempic, which can cost $1,000 a month, is an opportunity apparently too good for them to pass up. New research released by McAfee, a computer and cybersecurity company, says that phishing scams targeting consumers interested in weight loss drugs like Ozempic, Wegovy, and Semaglutide rose 183% from January to April compared to the previous three months.

Persons: McAfee, — Organizations: Service, McAfee, Business

☆ Top doctor warns against taking weight loss drugs such as Ozempic to get 'beach body ready' for summer
▼ + stars: | 2024-06-15 | by ( Nathan Rennolds | ) www.businessinsider.com time to read: +3 min

download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewOne of the UK's top doctors has warned people against taking weight loss drugs such as Ozempic to get "beach body ready" for summer, saying they should not be seen as a "quick fix." "Drugs including Ozempic and Wegovy should only be used by people prescribed them for obesity or diabetes. Nevertheless, weight loss drugs such as Ozempic and Wegovy have soared in popularity over the last year. AdvertisementThere are currently three semaglutide products approved by the US Food and Drug Administration — Ozempic injection, Wegovy injection, and Rybelsus tablets.

Persons: —, Stephen Powis, Powis, I'm, Vicky Price Organizations: Service, National Health Service, Business, NHS Confederation, Society for Acute, Novo Nordisk, Europe's, Statistics, US Food and Drug Administration Locations: England, London, Danish, Statistics Denmark

☆ Ozempic Cuts Risk of Chronic Kidney Disease Complications, Study Finds
▼ + stars: | 2024-05-24 | by ( Dani Blum | ) www.nytimes.com time to read: +1 min

Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial, the results of which were published on Friday. The findings could transform how doctors treat some of the sickest patients with chronic kidney disease, which affects more than one in seven adults in the United States but has no cure. The trial, funded by Ozempic maker Novo Nordisk, was so successful that the company stopped it early. Dr. Martin Holst Lange, Novo Nordisk’s executive vice president of development, said that the company would ask the Food and Drug Administration to update Ozempic’s label to say it can also be used to reduce the progression of chronic kidney disease or complications in people with Type 2 diabetes. Diabetes is a leading cause of chronic kidney disease, which occurs when the kidneys don’t function as well as they should.

Persons: Ozempic, ”, Katherine Tuttle, Martin Holst Lange, Novo, Subramaniam Pennathur Organizations: University of Washington School of Medicine, Renal Association, The New England, of Medicine, Novo Nordisk, and Drug Administration, Diabetes, Michigan Medicine Locations: United States, Stockholm, The

☆ Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds
▼ + stars: | 2024-05-24 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Diabetes is a key risk factor for kidney disease, which is one of the leading causes of death in the United States and worldwide; about 1 in 3 people with diabetes also has chronic kidney disease, according to the US Centers for Disease Control and Prevention. But new research shows that weekly injections of semaglutide cut the risk of severe outcomes from diabetic kidney disease by about 24%. The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease. “Kidney disease attributed to diabetes, or diabetic kidney disease, is one of the most common and deadly complications of diabetes. Yet, unfortunately, there’s very low awareness around it,” said Dr. Katherine Tuttle, chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology.

Persons: ”, Vlado Perkovic, “ Semaglutide, Martin Holst Lange, Katherine Tuttle, ” It’s, Tuttle, semaglutide, It’s, Dr, Sanjay Gupta, White, ” Tuttle Organizations: CNN, Diabetes, US Centers for Disease Control, New England, of Medicine, European Renal Association Congress, University of New, University of New South Wales Sydney, Novo Nordisk, American Society of Nephrology, Providence Inland Northwest Health, Health Sciences, University of Washington, CNN Health Locations: United States, University of New South, Danish, American

☆ Ozempic users will soon get their own heat-and-eat meals
▼ + stars: | 2024-05-21 | by ( Alex Bitter | ) www.businessinsider.com time to read: +3 min

Read previewFrozen meals are one of the latest ways that big consumer brands are trying to cater to users of weight loss drugs like Ozempic and Wegovy. The lineup is designed for GLP-1 weight loss medication users and will include items like sandwich melts and grain bowls with chicken. Related storiesThe meals are "portion-aligned to a weight loss medication user's appetite" and contain high amounts of fiber, protein, and essential nutrients, Nestlé said. Vital Pursuit shows how the food industry is adapting to the rise of GLP-1 drugs. That price would undercut other forms of the weight loss drug.

Persons: —, Nestlé, They're, Steve Presley, Sean Connolly Organizations: Service, Business, North, American Pharmacists Association, Vital, Costco Locations: Nestlé

☆ People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies confirm
▼ + stars: | 2024-05-20 | by ( Brenda Goodman | ) edition.cnn.com time to read: +9 min

Injected medications called GLP-1 agonists are in high demand because they have proved to be so effective for weight loss. The difference, which was statistically significant, amounted to a 52% increased risk of being diagnosed with stomach paralysis while on a GLP-1 medication. Compared with those who were not taking a GLP-1 medication, those who did were about 66% more likely to be diagnosed with gastroparesis. This study found that 0.53% of patients on GLP-1 medications were diagnosed with stomach paralysis, or about 1 case of gastroparesis for every 200 people taking the drugs. People taking GLP-1 medications were also more likely to have nausea and vomiting or gastroesophageal reflux disease (GERD) and to be prescribed a proton pump inhibitor.

Persons: gastroparesis, GERD, ”, Prateek Sharma, Sharma, ” Sharma, Michael Camilleri, “, Camilleri, It’s, who’d, Dr, Sanjay Gupta, it’s Organizations: CNN, Drugmaker, Nordisk, University Hospitals, Diabetes, University of Kansas, University of Kansas School of Medicine, American Society, Mayo Clinic, CNN Health Locations: Washington, Cleveland, GLP, Mayo

☆ Celebrities can't lose weight without people speculating they're on Ozempic. Here's who's addressed rumors — as Kelly Clarkson denies she's taken it.
▼ + stars: | 2024-05-14 | by ( Rachel Hosie | Amber Middleton | ) www.businessinsider.com time to read: +1 min

Ozempic and Wegovy are both forms of semaglutide, a drug originally developed for diabetes. OEL SAGET/AFP via Getty ImagesOzempic and Wegovy are the brand names used by the drug manufacturer, Novo Nordisk. Tirzepatide, marketed as Mounjaro for diabetes, is a similar "game-changer" drug, and has been approved for weight loss under the name Zepbound. Ozempic has become the byword for semaglutide and similar drugs that cause weight loss (known as GLP-1s), regardless of which brand a person is taking or why. They work by suppressing appetite, but side effects such as muscle loss, nausea, and diarrhea have been reported, and it's common to regain the weight after stopping treatment.

Persons: SAGET, Ozempic Organizations: Getty, Novo Nordisk, Semaglutide, FDA Locations: AFP

☆ What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
▼ + stars: | 2024-05-13 | by ( Meg Tirrell | ) edition.cnn.com time to read: +10 min

CNN —New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use. A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo. It was sustained for up to four yearsThe results showed that the 10% average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years. Patients stayed on the medicine while they sustained the weight loss. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo.

Persons: Wegovy, –, ”, Harlan Krumholz, Dr, Donna Ryan, Eli Lilly, wasn’t, they’d, Daniel Drucker, it’s, John Deanfield, Krumholz, Drucker, GLP, Sanjay Gupta Organizations: CNN, Yale University, Yale New Haven Hospital, drugmaker, Nordisk, Novo Nordisk, European, Obesity, Nature, Pennington Biomedical Research, University of Toronto, University College London, CNN Health Locations: Baton Rouge , Louisiana, Novo

☆ Oprah Winfrey: I set an unrealistic standard for dieting
▼ + stars: | 2024-05-09 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +4 min

New York CNN —Oprah Winfrey said on Thursday evening that she has long played a role in promoting unhealthy and unrealistic diets. I cannot tell you how many weight loss shows and makeovers I have done and they have been a staple since I’ve been working in television,” she said. Winfrey told People Magazine in December that she has added a “weight-loss medication to her regimen” but didn’t specify which drug. Winfrey and WeightWatchersWinfrey left the board of WeightWatchers, ending a nearly decade-long stint as a director of the beleaguered company, in February. “I will say that I was on the board at the time there were discussions about whether or not WeightWatchers would move into weight loss medications,” Winfrey said on Thursday.

Persons: Oprah Winfrey, ”, I’ve, makeovers, Winfrey, Rebel Wilson, Amber Riley, Sima Sistani, Sistani, WeightWatchers Winfrey, ” Winfrey, Oprah, WeightWatchers, ” WeightWatchers, Jimmy Kimmel, “ Organizations: New, New York CNN, YouTube, WeightWatchers, Magazine, National Museum of, Goldman Sachs Locations: New York

☆ ‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their safety if they do
▼ + stars: | 2024-05-08 | by ( Mira Cheng | Meg Tirrell | ) edition.cnn.com time to read: +12 min

“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.

Persons: CNN — Catera Bentley, Bentley, ”, “, ” Bentley, she’d, —, ‘, ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, —, Colorado

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ Barbra Streisand ‘forgot the world is reading’ when she asked Melissa McCarthy if she took Ozempic on Instagram
▼ + stars: | 2024-04-30 | by ( Alli Rosenbloom | ) edition.cnn.com time to read: +1 min

CNN —Barbra Streisand is addressing a divisive comment she wrote under a photo that actor Melissa McCarthy posted on her Instagram page on Monday. In the comment, Streisand asked McCarthy if she took Ozempic – a popular weight loss medication, among its other functions – spurring backlash online. “Below them was a photo of my friend Melissa McCarthy who I sang with on my Encore album,” she wrote. I forgot the world is reading!”CNN has reached out to representatives for McCarthy and Streisand for comment. Ozempic is a brand name for the generic drug semaglutide, and is approved by the US Food and Drug Administration to treat diabetes.

Persons: Barbra Streisand, Melissa McCarthy, Streisand, McCarthy, Ozempic, she’d, ”, “, Adam Shankman Organizations: CNN, Center, US Food and Drug Administration

☆ How Supplement Stores Are Trying to Tap Into the Ozempic Boom
▼ + stars: | 2024-04-29 | by ( Jordyn Holman | ) www.nytimes.com time to read: 1 min

As diabetes and weight-loss drugs like Ozempic and Wegovy took off in the last few years, many people turned away from established diet and nutrition products. Now, two retailers that specialize in nutritional supplements — GNC and the Vitamin Shoppe — are trying new approaches to win over people who are taking those drugs or who are interested in them. GNC is dedicating a wall of supplements in its more than 2,300 stores to products that it believes will appeal to people on Ozempic, which contains the compound semaglutide, and other drugs that are known as GLP-1 medicines. The chain is also training workers to help customers assess which substances could help them manage common side effects of those prescription drugs. Michael Costello, chief executive of GNC, said his company saw a “big opening” in helping individuals taking such drugs for weight loss.

Persons: Wegovy, Michael Costello

☆ Ozempic and Wegovy Have Health Benefits Beyond Weight Loss - The New York Times
▼ + stars: | 2024-04-24 | by ( David Wallace-Wells | ) www.nytimes.com time to read: +3 min

Last year was called the year of Ozempic, though it was also a year of Ozempic backlash and Ozempic shortages, which could persist for years. Even so, we appear very far from a peak for GLP-1 drugs, like Ozempic and Wegovy, which are powered by a molecule called semaglutide, and Mounjaro, which uses its cousin tirzepatide. It seems possible to imagine a future in which almost everyone is taking some variety of GLP-1 drug, and with a pretty good reason to do so. Patients on Ozempic and Wegovy can lose 15 to 20 percent or more of their weight in a little over a year, and if they stay on the drugs, the weight tends to stay off. Semaglutide has been shown to eliminate or reduce the need for insulin among those with recent-onset Type 1 diabetes.

Persons: tirzepatide, Wegovy, we’ve, Semaglutide Locations: Alzheimer’s

☆ How Ozempic Is Transforming a Small Danish Town
▼ + stars: | 2024-04-20 | by ( Eshe Nelson | ) www.nytimes.com time to read: +1 min

As the sun sets over the harbor in Kalundborg, a small town about 60 miles west of Copenhagen, light streams through the glass walls of Shaun Gamble’s cafe and bathes his afternoon customers in a warm glow. Nearby, at a sprawling manufacturing plant, Novo Nordisk makes nearly all of its semaglutide, the active ingredient in the company’s wildly popular diabetes and obesity treatments Ozempic and Wegovy. It’s the largest manufacturing investment in Denmark by a company, and it’s happening in this town of fewer than 17,000 people. Novo Nordisk plans to add 1,250 jobs to the existing 4,500 employees at the Kalundborg plant. A highway is being extended; investors are snapping up houses and planning new construction; universities have begun offering biotech courses to feed Novo Nordisk and nearby businesses with workers.

Persons: Shaun Gamble’s Organizations: Novo Nordisk, Nordisk Locations: Kalundborg, Copenhagen, Denmark, Novo

☆ Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
▼ + stars: | 2024-04-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City

☆ EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
▼ + stars: | 2024-04-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator said Friday. The review examined several drugs from Novo Nordisk , including Wegovy and Ozempic. Clinical trials from Novo Nordisk and Eli Lilly have not demonstrated a link between GLP-1s and suicidal thoughts. The probe also included other active ingredients in older weight loss and diabetes drugs, including dulaglutide, exenatide and lixisenatide. Results from another study conducted by the agency also did not support a link between GLP-1 drugs and the risk of suicidal thoughts.

Persons: Eli Lilly, couldn't, Liraglutide Organizations: Novo Nordisk, European Union, European Medicines Agency, U.S . Food, Drug Administration, EMA, Icelandic Medicines Agency Locations: London, Britain, Novo, U.S, GLP, Wegovy, Ozempic

☆ Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds
▼ + stars: | 2024-04-06 | by ( Jen Christensen | ) edition.cnn.com time to read: +8 min

The study, published Saturday in the New England Journal of Medicine, showed how the drug helped people with Type 2 diabetes who also had one of the most common kind of heart failure, obesity-related heart failure with preserved ejection fraction. Obesity-related heart failure with preserved ejection fraction can severely limit a person’s ability to participate in the activities of daily life. Often, people with type 2 diabetes who have this kind of heart failure have a more severe form than those who don’t have diabetes. People with a more severe form of heart failure sometimes don’t respond as well to medication as those with less severe disease. One death in the Wegovy group and four in the placebo group were related to cardiovascular issues.

Persons: Wegovy, Ozempic, Dr, Mikhail Kosiborod, “, ” Kosiborod, Naveed Sattar, ” Sattar, Sanjay Gupta, Kosiborod, ” Organizations: CNN, New England, of Medicine, Novo Nordisk –, US Food and Drug Administration, FDA, St, University of Glasgow, Science Media, CNN Health, American College of Cardiology Locations: Asia, Europe, North, South America, Kansas City , Missouri, Atlanta

Search resuls for: "semaglutide"

25 mentions found